MAP2K7 and melanoma: Most melanoma patients harbor mutations in the mitogen-activated protein kinase (MAPK) pathway (BRAF-MEK-ERK) (BRAFV600E being the most common) and therefore, benefit from targeted therapies against MAPK pathway (BRAF and MEK inhibitors).